NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect

Toshiki Etani(Nagoya City University), Satoru Takahashi(Hamamatsu University School of Medicine)
Oncotarget
December 26, 2014
Cited by 46


Related Papers